

IND-SWIFT LABORATORIES LIMITED
REGD. OFFICE: SCO 850, SHIVALIK ENCLAVE, NAC MANIMAJRA, CHANDIGARH

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST, MARCH 2012

(₹ In Lacs)

Particulars	STANDALONE					CONSOLIDATED	
	Quarter Ended 31.03.2012	Quarter Ended 31.12.2011	Quarter Ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
(a) Net Sales/Incomes from Operations	35861.53	35178.11	30341.34	132068.13	101972.54	140917.45	103704.35
Other Income	207.76	702.31	373.41	1771.43	1041.67	1881.47	1041.67
Total Net Sales / Operating Income	36069.30	35880.41	30714.75	133839.56	103014.21	142798.92	104746.02
Total Expenditure :							
a Cost of Materials Consumed	21356.47	23993.44	14359.14	72049.44	43385.24	80178.98	90231.63
b Purchase of stock in Trade	9997.44	8670.43	13865.42	40034.57	45653.33	40034.57	45653.33
c (Increase) /decrease in stock in trade	(1064.04)	(5969.64)	(4361.03)	(8120.72)	(12950.10)	(8120.72)	(12950.10)
d Staff cost	799.09	677.68	461.32	2715.46	1999.61	2869.28	1999.35
e Depreciation	308.02	1132.64	1064.89	3986.09	3851.64	3986.09	3851.64
f Impairment of Assets	(100.00)	20.00	41.35	0.00	241.35	0.00	241.35
g Other expenditure	1972.17	2100.01	1928.71	7870.88	6840.18	8173.82	7190.40
TOTAL	33269.13	30624.56	27259.81	118535.73	89021.25	127122.03	90564.28
Profit from Operations before Other Income, Interest & Exceptional Items	2800.16	5255.85	3454.94	15303.83	13992.95	15676.89	14181.74
Other Income	177.00	0.00	0.00	1450.41	0.00	1450.41	0.00
Profit before Interest & Exceptional Items	2977.16	5255.85	3454.94	16754.24	13992.95	17127.30	14181.74
Interest	2128.49	2266.98	1944.11	8454.71	5587.18	8472.63	5589.70
Profit after Interest but before Exceptional Items	848.68	2988.87	1510.83	8299.54	8405.78	8654.67	8592.04
Extra ordinary item (Reverse of Previous year Provision)	0.00	0.00	(72.80)	0.00	(306.77)	0.00	(306.77)
Profit (+)/ Loss (-) from Ordinary Activities before tax	848.68	2988.87	1583.63	8299.54	8712.55	8654.67	8898.81
Provision for taxation	261.26	595.68	335.85	1746.21	1796.54	1756.22	1798.20
Income Tax adjustment of Previous Year	0.71	0.00	(4.56)	(46.63)	(4.56)	(46.63)	(4.56)
Mat Credit Entitlement	(261.26)	(595.68)	(335.85)	(1746.21)	(1796.54)	(1746.21)	(1796.54)
Provision for deferred Tax	(987.60)	144.86	(1051.29)	(297.84)	(44.51)	(224.78)	(44.51)
Net Profit /Loss	1835.57	2844.01	2639.48	8644.01	8761.62	8916.08	8946.21
Provision for dividend on Equity Shares	-	-	-	-	342.23	-	342.23
Provision for Equity dividend Tax	-	-	-	-	56.84	-	56.84
Transfer to General reserve	-	-	-	-	438.08	-	438.08
Retained Profit	1835.57	2844.01	2639.48	8644.01	7924.47	8916.08	8109.06
Paid up Equity Share Capital	3794.55	3638.45	3,422.31	3,794.55	3422.31	3,794.55	3422.31
Reserve excluding revaluation reserves	-	-	-	56131.39	44913.28	56206.80	44716.63
EPS Rs.							
Basic	5.12	8.06	8.96	24.10	29.76	25.48	30.38
Diluted	4.94	7.46	8.31	23.25	27.57	24.58	28.15
Public Shareholding							
Numbers of shares	19396344	19397124	19174724	19396344	19174724	19396344	19174724
% of Shareholding	51.12%	53.31%	56.03%	51.12%	56.03%	51.12%	56.03%
Promoters and Promoter group shareholding							
a) Pledged/Encumbered	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered							
Number of Shares	18549126	16987346	15048346	18549126	15048346	18549126	15048346
Percentage of shares (as a % of the total share capital of the company)	48.88%	46.69%	43.97%	48.88%	43.97%	48.88%	43.97%

Audited Statements of Assets and Liabilities		(Rs. In Lacs)			
	As at	As at	As at	As at	
	31.03.2012	31.03.2011	31.03.2012	31.03.2011	
	STANDALONE		CONSOLIDATED		
I. EQUITY AND LIABILITIES					
(1) Shareholders' Funds					
a) Share Capital	3794.55	3422.31	3794.55	3422.31	
b) Reserves & Surplus	78308.61	53582.61	78384.03	53385.96	
c) Money received against share warrants	271.22	1002.38	271.22	1002.38	
(2) Non-current liabilities					
(a) Long-term borrowings	71104.29	59940.07	71104.29	59940.07	
(b) Deferred Tax Liabilities(Net)	4037.67	4335.51	4110.73	4335.51	
(c) Other Long term liabilities	2344.43	1706.00	2344.43	1706.00	
(3) Current Liabilities					
(a) Short term Borrowings	30183.08	21979.01	30183.08	21979.01	
(b) Trade Payable	23847.66	23264.41	25405.04	23533.75	
(c) Other current liabilities	4887.69	1642.16	4453.92	1820.35	
(d) Short term Provisions	1746.21	2195.61	1757.42	2197.26	
TOTAL	220525.41	173070.06	221808.71	173322.59	
II. ASSETS					
Non-Current Assets					
(1) (a) Fixed Assets					
(i) Tangible Assets	90203.33	55062.08	90203.33	55062.08	
(ii) Intangible Assets	13669.21	15083.36	13775.77	15108.44	
(iii) Capital work in Progress	29422.86	31529.62	29422.86	31529.62	
(iv) Assets held for disposal	223.36	223.36	223.36	223.36	
	133518.76	101898.43	133625.33	101923.51	
Accumulated depreciation	13229.46	15661.12	13229.46	15661.12	
Net Block	120289.31	86237.31	120395.87	86262.40	
(b) Non-Current investment	2723.03	2807.96	1709.56	1794.48	
(c) Long-term loans & advances	164.76	207.31	167.49	209.66	
(2) Current assets					
(a) Current investment	210.00	3010.00	210.00	3010.00	
(b) Inventories	49380.92	36554.71	49427.53	36554.71	
(c) Trade receivables	28180.28	28705.45	30378.41	29384.55	
(d) Cash and Cash equivalents	4622.96	4842.25	4692.32	5409.89	
(e) Short-term loans and advances	14954.15	10705.06	14957.22	10707.08	
(f) Foreign Currency Translation	0.00	0.00	(129.69)	(10.18)	
TOTAL	220525.41	173070.06	221808.71	173322.59	

Notes :-

1. The Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 30th May, 2012.
2. During the quarter ended March, 2012, Company has allotted 15,61,000 equity shares upon conversion of Zero Coupon Warrants raising thereby a sum of Rs.965.87 lacs. The funds raised were utilized for Derabassi, Jammu and R&D Mohali facility expansion including capital advances and augmentation of NWC.
3. A major fire occurred at M/s Dashmesh Medicare Private Limited, a loan licensee for ISLL for a main product, on continuous basis. Impact On ISLL could not be ascertained as the site is not released to Dashmesh yet.
4. The Consolidated result includes the results of the US and Singapore Subsidiaries.
5. Information on Investor Complaints for the quarter. Opening Balance NIL, Received Nil, Redressed Nil, Closing Balance NIL.
6. The previous period figures have been re-grouped and re-arranged wherever necessary.
7. The Company is exclusively in the Pharmaceutical business segment.

For Ind-Swift Laboratories Ltd.

Sd/-

(N.R. Munjal)

Vice Chairman cum
Managing Director

Place : Chandigarh
Date : 30.05.2012